Treatment of human intestinal cryptosporidiosis: A review of published clinical trials

Ajib Diptyanusa, Ika Puspa Sari

Abstract

The global burden of diarrhea caused by Cryptosporidium parasite is underestimated. In immunocompromised hosts, chronic and severe presentation of intestinal cryptosporidiosis can result in long-term morbidity and high illness costs. The evidence of effective treatments for cryptosporidiosis has been lacking. We reviewed the published clinical trials to bring forward the feasible therapeutic options of human cryptosporidiosis in various populations and settings according to clinical improvement and parasite clearance rates. A total of 42 studies consisting of the use of nitazoxanide, paromomycin, macrolides, somatostatin analogues, letrazuril, albendazole, rifaximin, miltefosine, clofazimine, and colostrum were included in the review. The trials were mostly conducted in small number of individuals infected with human immunodeficiency virus (HIV), and there is inadequate data of controlled trials to suggest the use of these treatment modalities. Nitazoxanide was reported to be highly efficacious only in immunocompetent hosts and was found to be superior to paromomycin in the same group of patients. Macrolides showed no effective results in both clinical and parasitological improvement. Human bovine colostrum should possibly be administered as one of complementary therapeutic modalities along with other antimicrobials to reach optimal parasite eradication. Other trials of therapeutic modalities were terminated due to futility. Currently, available data is intended to aid the development of strategies for improving access to treatments in different clinical settings, as well as to help guide further studies on treatments of human intestinal cryptosporidiosis.

1. Introduction

Cryptosporidium belongs to the Phylum Apicomplexa, which infects a wide range of vertebrate hosts, including humans (Gerace et al., 2019). This intracellular protozoan parasite is generally transmitted through ingestion of food or water contaminated with its oocysts (Samie et al., 2015). Cryptosporidium infects the gastrointestinal epithelium, causing diarrhea that is mostly mild yet sometimes debilitating in certain groups (McCann, 2019). The first human cases of cryptosporidiosis were noticed in 1976, and the parasite was then recognized as an opportunistic pathogenic parasite associated with diarrhea in immunocompromised individuals (Meisel et al., 1976; Nime et al., 1976). Along with the increasing incidence of human immunodeficiency virus (HIV) infection worldwide in the early 1980s, Cryptosporidium became more widely known as acquired immunodeficiency syndrome (AIDS)-defining disease (Ahmadpour et al., 2020; Ashigbie et al., 2021). Outbreaks of human cryptosporidiosis are not only reported in developing countries, but also in industrialized countries (Mac Kenzie et al., 1994; Shirley et al., 2012; Ursini et al., 2020), mainly attributable to its low infective dose, the presence of wide range of animal reservoirs, and its ability to withstand chlorination (Adeyemo et al., 2019; Bouzid et al., 2013; DuPont et al., 1995). While the disease may be asymptomatic in immunocompetent human hosts, cryptosporidiosis is more likely to be chronic and more severe in immunocompromised individuals, and may result in high illness costs and long-term manifestations such as post-infectious inflammatory bowel syndrome in both immunocompetent and immunocompromised groups (Jadallah et al., 2017; Monge et al., 2019; O’Connor R et al., 2011). Cryptosporidium has also been recognized as the leading cause of severe and life-threatening diarrhea in children, particularly in developing countries (Khalil et al.,...
Despite its long history of recognition over the past decades, the evidence of effective antiparasitic treatments for cryptosporidiosis has been lacking. Even with the initiation of effective antiretroviral (ARV) therapy to restore the immune function of immunocompromised hosts, chronic diarrhea caused by cryptosporidiosis is associated with high mortality (Dillingham et al., 2009). Nitazoxanide is currently the only drug approved by the FDA to treat cryptosporidiosis (Checkley et al., 2015), yet it is unavailable in many developing countries where the disease burden is prominent. Diverse therapeutic modalities have been studied in case reports, case series and clinical trials with different results. However, there is inadequate data to recommend the use of some of the studied treatment approaches. The current review aimed to address the feasible therapeutic options of human cryptosporidiosis in various populations and settings according to published clinical trials.

2. Methods

Literature searching was performed using three online databases, including PubMed (MEDLINE), EMBASE, and Google Scholar. Inclusion criteria were published results of clinical trials written in English and related to the treatment of human intestinal cryptosporidiosis. Truncations and Boolean terms were utilized to facilitate literature searching. Combinations of the following search terms were used for article explorations: Cryptosporidium, treatment, drug, trial, random, nitazoxanide, paromomycin, azithromycin, spiramycin, roxithromycin, somatostatin, letrazuril, albendazole, rifaximin, miltefosine, clofazimine, and colostrum. The search yielded a total of 271 articles. After removing duplicates and applying inclusion and exclusion criteria, 42 studies were included in this review (Fig. 1).

3. Results

Overall, included studies were published from late 1980s through 2020, the majority of which were published in the 1990s (Table 1). The trials were mostly conducted in individuals living with HIV of various stages or other comorbid leading to immunosuppression. Open-label trials are defined as clinical trials, in which both study participants and researcher were aware of the treatment allocations in the study. In general, primary endpoints for these studies include clinical improvement that was defined as either abatement of diarrhea or reduced stool frequency or volume, and parasite clearance that was defined as either complete eradication or reduction of Cryptosporidium oocysts.

3.1. Nitazoxanide

Among the drugs proposed for the treatment of cryptosporidiosis, nitazoxanide is the most frequently studied. Various doses have been assigned in the studies as shown in Table 2. An open-label clinical trial in individuals living with HIV using the dose of 500 mg administered twice daily for 7 days resulted in 64% clinical improvement and 57% parasite clearance (Doumbo et al., 1997). A similar dose with a shorter treatment duration gave a better outcome in both clinical parameters and oocyst excretion (Rossignol et al., 2006). However, the study was conducted in healthy individuals with the potential for a positive impact on the overall treatment outcome. Better treatment responses after the use of nitazoxanide were also reported in immunocompetent hosts rather than those in immunocompromised hosts (Abaza et al., 2016; Amadi et al., 2002). Diarrhea episodes resolved within 3–5 days in immunocompetent group, and within 21–28 days in immunocompromised group (Abaza et al., 2016). Similarly, another study also showed larger proportion of HIV-seronegative children had the diarrhea episodes resolved within 7 days after initiation of nitazoxanide (Amadi et al., 2002).
Table 1
Summary of reviewed studies on treatments of human intestinal cryptosporidiosis.

| Treatment modalities | Publication year | Country | Study design           | Population Details | Size | Ref |
|----------------------|------------------|---------|------------------------|--------------------|------|-----|
| Nitazoxanide         | 1997             | Mali    | Open-label clinical trial | >12 yo with advanced HIV | 14   | Dounbou et al. (1997) |
|                      | 1998             | Mexico  | RCT                    | 18-65 yo with HIV   | 54   | Rossignol et al. (1998) |
|                      | 2001             | Egypt   | RCT                    | 1-65 yo healthy individuals | 99   | Rossignol et al. (2001) |
|                      | 2002             | Zambia  | RCT                    | ≥ 3 yo with HIV     | 96   | Amadi et al. (2002)    |
|                      | 2006             | USA     | Open-label clinical trial | ≥ 3 yo with HIV     | 357  | Rosignol (2006)        |
|                      | 2006             | Egypt   | RCT                    | ≥ 12 yo healthy individuals | 86   | Rossignol et al. (2006) |
|                      | 2009             | Zambia  | RCT                    | 1-11 yo with HIV    | 52   | Amadi et al. (2009)    |
|                      | 2013             | Egypt   | Open-label clinical trial | 6 mo to 10 yo with malnutrition | 135  | Hussien et al. (2013) |
|                      | 2015             | Pakistan| Open-label clinical trial | >16 yo healthy individuals | 58   | Ali and Kumar (2015)   |
|                      | 2016             | Egypt   | RCT                    | 1-12 yo immune-competent and -compromised individuals | 120  | Abaza et al. (2016)   |
| Paromomycin          | 1993             | USA     | Open-label clinical trial | 30-49 yo with HIV   | 7    | Fichtenbaum et al. (1993) |
|                      | 1994             | France  | Open-label clinical trial | 25-62 yo with HIV   | 24   | Bissuel et al. (1994)  |
|                      | 1994             | USA     | RCT                    | 25-38 yo with HIV (CD4 < 100 cells/uL) | 10   | White et al. (1994)    |
|                      | 1996             | USA     | Open-label clinical trial | Adults with HIV (CD4 ≤ 200 cells/uL) | 44   | Flanigan et al. (1996) |
|                      | 1998             | USA     | Open-label clinical trial | 23-44 yo with HIV (CD4 < 100 cells/uL) | 11   | Smith et al. (1998)    |
| Macrolides           | 1987             | Canada  | N of 1 trial           | 24 yo with HIV      | 1    | (Woolf et al., 1987)  |
|                      | 1988             | London  | Open-label clinical trial | All age with HIV    | 15   | Connolly et al. (1988) |
|                      | 1989             | South Africa | RCT                  | < 1 yo immune-compromised infants | 39   | Wittenberg et al. (1989) |
|                      | 1998             | Brazil  | Open-label clinical trial | 23-49 yo with HIV   | 24   | Sprinz et al. (1998)   |
|                      | 1998             | Brazil  | Open-label clinical trial | Adults with HIV     | 22   | Uip et al. (1998)      |
|                      | 1998             | Italy   | Open-label clinical trial | 30-47 yo with HIV (CD4 < 200 cells/uL) | 13   | Dionisio et al. (1998) |
|                      | 2002             | India   | RCT                    | 22-63 yo with HIV   | 41   | Kadappu et al. (2002)  |
|                      | 2015             | China   | RCT                    | >20 yo drug users   | 151  | Huang et al. (2015)    |
|                      | 1990             | Australia | RCT                  | Individuals with HIV | 5    | Nord et al. (1990)     |
|                      | 1990             | USA     | RCT                    | 31-46 yo with HIV   | 14   | McMeeking et al. (1990) |
|                      | 1992             | Germany | Open-label clinical trial | 1-54 yo with HIV and other immune deficiencies | 7    | Rump et al. (1992)     |
|                      | 1993             | Germany | Open-label clinical trial | 26-58 yo with HIV (CD4 < 100 cells/uL) | 7    | Flettenberg et al. (1993) |
|                      | 1996             | USA     | Open-label clinical trial | ≥ 18 yo with HIV (CD4 < 200 cells/uL) | 20   | Greenberg and Cello (1996) |
|                      | 2005             | Nigeria | Open-label clinical trial | ≥ 18 yo with HIV (CD4 < 200 cells/uL) | 20   | Florin et al. (2006)   |
| Bovine colostrum     | 1991             | USA     | Open-label clinical trial | 18-60 yo with HIV   | 15   | Cello et al. (1991)    |
|                      | 1991             | Spain   | Open-label clinical trial | 22-48 yo with HIV   | 18   | Romeu et al. (1991)    |
|                      | 1992             | Italy   | Open-label clinical trial | 37-70 yo with HIV (CD4 < 100 cells/uL) | 4    | Liberti et al. (1992)  |
|                      | 1992             | France  | Open-label clinical trial | ≥ 18 yo with HIV    | 21   | Girard et al. (1992)   |
|                      | 2009             | Italy   | Open-label clinical trial | 21-60 yo with HIV (CD4 < 100 cells/uL) | 13   | Moroni et al. (1993)   |
| Somatostatin analogue| 1991             | USA     | Open-label clinical trial | 21-59 yo with HIV (CD4 < 100 cells/uL) | 14   | Harris et al. (1994)   |
|                      | 1995             | Canada  | Open-label clinical trial | 27-57 yo with HIV (CD4 < 150 cells/uL) | 35   | Loeb et al. (1995)     |
|                      | 1999             | Italy   | Open-label clinical trial | 12-54 yo with HIV   | 10   | Amenta et al. (1999)   |
| Letrazuril           | 2002             | Zambia  | Open-label clinical trial | ≥ 18 yo with HIV (CD4 < 200 cells/uL) | 4    | Zulu et al. (2002)     |
| Rifaximin            | 2002             | Zambia  | Open-label clinical trial | ≥ 18 yo with HIV and malnutrition | 7    | Sinkala et al. (2011)  |
| Albenzadole          | 2011             | Zambia  | Open-label clinical trial | ≥ 18 yo with HIV (severe immunosuppression) | 20   | Tam et al. (2020)      |
| Miltefosine          | 2015             | Malawi  | RCT                    | 18-65 yo with HIV (severe immunsuppression) | 42   | Sindhux et al. (2014)  |
| Probiotics           | 2014             | India   | RCT                    | 6 months to 5 yo healthy children | 13   | (Wolf et al., 1987)    |

RCT: randomized clinical trial.
Additionally, other studies performed in healthy individuals revealed clinical improvement in terms of abatement of diarrhea up to 80–100% (Ali and Kumar, 2015; Rossignol et al., 2001) and eradicating parasite in 67% of the patients (Rossignol et al., 2001). Higher dose of nitazoxanide and longer duration of treatment did not substantiate higher cure rate in some studies (Amadi et al., 2009; Rossignol, 2006; Rossignol et al., 1998). Frequently reported side effects include gastrointestinal upset, fatigue, drowsiness, and headache (Ali and Kumar, 2015; Amadi et al., 2009; Rossignol, 2006; Rossignol et al., 1998, 2001, 2006). Scleral and urine discoloration have also been reported although uncommon (Amadi et al., 2009; Rossignol, 2006; Rossignol et al., 2001). According to the available published data regarding efficacy of nitazoxanide on human cryptosporidiosis in controlled trials, the benefit of nitazoxanide may be limited only to immunocompetent individuals. This is showed by shorter duration of diarrhea and better parasite clearance of healthy individuals compared to that of immunocompromised group (Abaza et al., 2016; Amadi et al., 2002). However, nitazoxanide did not demonstrate superiority over placebo in HIV individuals (Amadi et al., 2009; Rossignol et al., 1998). Nitazoxanide acts by inhibiting the pyrivate:ferredoxin oxidoreductase (PFOR), an enzyme essential for the metabolism of certain anaerobic bacteria and parasites (Hoffman et al., 2007). The PFOR in Cryptosporidium has an atypical arrangement in which the enzyme contains a C-terminal cytochrome P450 protein, hence Nitazoxanide action via PFOR remains debatable (Bartelt et al., 2018). Furthermore, observed better efficacy of nitazoxanide in immunocompetent patients, but less so or not at all in immunodeficient individuals might have suggested that host immunity contributed to drug effectiveness (Miyamoto and Eckmann, 2015).

### 3.2. Paromomycin

The efficacy of a non-absorbable aminoglycoside called paromomycin has also been studied in several clinical trials in the treatment of human cryptosporidiosis. Paromomycin inhibits protein synthesis by binding to the prokaryotic ribosomes of Cryptosporidium, hence preventing the infection (Marshall and Flanigan, 1992). In the published studies, all were conducted in individuals with immunocompromised status (Table 3). Some of the studies conducted in HIV-infected individuals with CD4 levels of ≤200 cells/μl resulted in clinical improvement of less than 50% and a low degree of parasite clearance (Flanigan et al., 1996; Hewitt et al., 2000; Smith et al., 1998; White et al., 1994). The 500 mg dose administered 3–4 times daily for 14–21 days demonstrated a lower cure rate compared to nitazoxanide. Paromomycin is associated with a low degree of side effects, including gastrointestinal upset, fatigue, drowsiness, and headache (Ali and Kumar, 2015; Amadi et al., 2009; Rossignol et al., 2006). Additionally, paromomycin is an effective agent for the treatment of Cryptosporidium, but its efficacy is lower than nitazoxanide in immunocompetent individuals.
Studies on the use of macrolides.

| Study                | Population | Size | Disease severity | Drug(s)                      | Regimen | Comparison | Follow up period | Clinical improvement | Parainse clearance |
|----------------------|------------|------|------------------|------------------------------|---------|------------|------------------|----------------------|---------------------|
| Fichtenbaum et al.   | 30-49 yo with HIV | 7    | All intensity    | 500 mg QID for 10–14 days   | None    | Weekly up to 6 months | 100%  | 75% (3/4)        |
| Bissuel et al.       | 25-62 yo with HIV | 24   | All intensity    | 1 g BID for 4 weeks, 500 mg BID for maintenance | None    | N/A, 3 stool samples | 92% (21/24) | 92% (21/24)       |
| Flanigan et al.      | Adults with HIV (CD4 <200 cells/ul.) | 44   | All intensity    | 500 mg QID for 4 weeks       | None    | Weeks 2 and 4 | 48% (21/44) | 46% (12/26)       |
| Smith et al.         | 23-44 yo with HIV (CD4 <100 cells/ul.) | 11   | Chronic           | 1 g paromomycin BID for 8 weeks plus 600 mg azithromycin | None    | Weeks 2, 4 and 12 | 27% (3/11) | 60% (6/10)        |
| White et al.         | 25-38 yo with HIV (CD4 <100 cells/ul.) | 10   | Chronic           | 500 mg OD for 8 weeks        | Placebo | Weekly during therapy | 50% (3/6) vs. 0 | 67% (4/6) vs. 0 |
| Hewitt et al.        | >13 yo with HIV (CD4 <150 cells/ul.) | 31   | All intensity     | 500 mg QID for 21 days       | Placebo | Weeks 1, 3, 4, 6, and 9 | 47% (8/17) vs. 36% (5/14) | 35% (6/17) vs. 29% (4/14) |
| Hussien et al.       | 6 to 10 yo with malnutrition | 135  | All intensity     | 25 mg/kg/d For 14 days       | Nitazoxanide 100–200 mg BID for 3 days | At the end of treatment | 69% (31/45) vs. 87% (39/45) | 69% (31/45) vs. 87% (39/45) |

P < 0.05.
Not statistically significant.
NS: not statistically significant.
* Either complete eradication or reduction of oocyst number.

days did not seem to give a significantly better outcome in this population compared to placebo (Hewitt et al., 2000; White et al., 1994). Higher dose of paromomycin and the addition of azithromycin for longer treatment duration also yielded sub-optimal results (Smith et al., 1993). Nevertheless, there were studies that reported 92–100% clinical improvement along with 75–92% parasite eradication rate after the

Studies on the use of macrolides.

| Study                | Population | Size | Disease severity | Drug(s)                      | Regimen | Comparison | Follow up period | Clinical improvement | Parainse clearance |
|----------------------|------------|------|------------------|------------------------------|---------|------------|------------------|----------------------|---------------------|
| Huang et al.         | >20 yo drug users | 151  | Asymptomatic     | Acetylsalicylamycin plus Garlicin | 200 mg plus 40 mg QID for 7 days | Placebo | Day 7 | N/A | 92% (35/38) vs. 62% (21/34) |
| Dionisio et al.      | 30-47 yo with HIV (CD4 <200 cells/ul.) | 13   | Chronic and relapsed cryptosporidiosis | Azithromycin | 500 mg OD for 30–40 days | Azithromycin 1 g OD for 21–50 days and 1.5 g OD for 20 days | Monthly | 83% (5/6) vs. 67% (2/3) vs. 75% (3/4) | 83% (5/6) vs. 67% (2/3) vs. 75% (3/4) |
| Kadappu et al.       | 22-63 yo with HIV | 41   | All intensity    | Azithromycin | 500 mg OD for 5 days | Azithromycin 500 mg OD for 7 days and for 14 days | Days 5, 7, 14 | 100% in all treatment arms | 0 vs. 0 vs. 0 vs. 0 |
| Connolly et al.      | All age with HIV | 15   | N/A              | Erythromycin | 500 mg QID for 7 days | Spiramycin 500 mg QID for 7 days | Day 14 | 100% in all treatment arms | 0 vs. 0 |
| Spinzl et al.        | 23-49 yo with HIV | 24   | Chronic           | Roxithromycin | 300 mg BID for 4 weeks | None | Week 6 | 79% (19/24) | 50% (12/24) |
| Up et al.            | Adults with HIV | 22   | All intensity    | Roxithromycin | 300 mg BID for 4 weeks | None | Week 6 | 27% (6/23) | 68% (15/22) |
| Woolf et al.         | 24 yo with HIV | 1    | Severe diarrhea  | Spiramycin | 1 g TID for 7 days | None | N/A | Relapsed | None |
| Wittenberg et al.    | <1 yo immune-compromised infants | 39   | N/A              | Spiramycin | 75 mg/kg/d For 5 days | Placebo | Regularly until discharged | N/A | 38% (8/21) vs. 33% (6/18) |

P < 0.05.
Not statistically significant.
* Either abatement of diarrhea or reduced stool frequency or volume.
* Either complete eradication or reduction of oocyst number.
administration of paromomycin (Bissuel et al., 1994; Fichtenbaum et al., 1993). However, these research did not give detailed characterization on the severity of patients’ immunocompromised status and were conducted in a relatively small population. Another randomized controlled trial (RCT) conducted in children reported inferior cure rate of paromomycin when compared to nitazoxanide (69%-87%) (Russien et al., 2013). However, the latter study was conducted in immunocompetent children. Other than gastrointestinal upset, an alarming side effect of paromomycin was elevated alkaline phosphatases (Hewitt et al., 2000). Reported clinical trials on the use of paromomycin as the treatment of human cryptosporidiosis remain lacking, possibly due to the consistently low efficacy despite extended therapeutic regimen.

3.3. Macrolides

Table 4 shows the use of macrolides in human cryptosporidiosis included in the current review. The earliest trials on the treatment of cryptosporidiosis include the use of macrolide antibiotics in both in vitro and in vivo studies. Azithromycin is one of the macrolide antibiotics widely used in these studies, particularly after being found to inhibit the growth of Cryptosporidium in culture medium and in immunosuppressed rats (Giacometti et al., 1996; Rehg, 1991). Two studies conducted in HIV-infected adults showed 67%-100% clinical improvement with doses ranged from 500 mg to 1.5 g (Dionisio et al., 1998; Kadappu et al., 2002). A larger dose did not seem to contribute much in the abatement of diarrhea episodes and parasite clearance in these studies. In contrast, longer treatment duration using 500 mg dose over 14 days yielded better oocyst reduction up to 83% (Dionisio et al., 1998; Kadappu et al., 2002).

Another case report also showed highly efficacious results in children with cancer using the dose of 10 mg/kg on day 1 and 5 mg/kg on days 2 through 10 (Hicks et al., 1996).

Another macrolide antibiotic, roxithromycin, has also been proposed as one of the therapeutic options for human cryptosporidiosis. However, both published trials in HIV individuals showed unconvincing results, demonstrating a wide range of cure rates: 27-79% for clinical improvement and 50%-68% for parasite clearance (Sprinz et al., 1998; Uip et al., 1998). Spiramycin, in general did not provide clinical benefits in both immunocompetent and immunocompromised children when compared to placebo (Saez-Llorens et al., 1989; Wittenberg et al., 1989). Conversely, the use of acetylated spiramycin in asymptomatic individuals showed a 92% oocyst reduction rate (Huang et al., 2015). Despite varying results in Cryptosporidium oocyst reduction, using azithromycin, erythromycin, and roxithromycin yielded desirable outcomes as abatement in diarrhea episodes (Table 4). Other macrolides, namely clarithromycin, has been studied as the chemophylaxis for intestinal cryptosporidiosis in individuals with HIV (Jordan, 1996).

Nevertheless, clinicians must bear in mind that HIV-infected individuals with deficient CD4 levels might have been infected with other opportunistic infections, including infection caused by Mycobacterium avium complex, as resistance strains to azithromycin and clarithromycin have been reported (Matteelli et al., 1998); hence complicate treatment for the infection. Reported side effects on the use of macrolides include nausea, vomiting, and abdominal pain (Connolly et al., 1988; Dionisio et al., 1998; Uip et al., 1998), as well as elevated liver transaminases (Sprinz et al., 1998). Despite the seemingly well performance of macrolides in treating human cryptosporidiosis, results of these controlled trials also showed relapse of diarrhea episodes and minimum parasite clearance. Abatement of diarrhea in the study subjects might have been due to treated unrecognized co-infections causing diarrhea and not the cryptosporidiosis itself, as co-infections are common and attributing diarrhea to only single pathogen is difficult (Kotloff et al., 2013). This should emphasize the ineffectivity of macrolides as the drug of choice for intestinal cryptosporidiosis.

3.4. Somatostatin analogue

Somatostatin, or the growth hormone-inhibiting hormone (GHIH), has shown inhibitory effects on gastrointestinal hormones and immunomodulatory actions, particularly in the jejunum, hence its use in HIV patients with secretory diarrhea refractory to other forms of therapy (Bai et al., 2018; Katz et al., 1988). Subcutaneous injection of 50 mcg to 500 mcg of octreotide for over 2 weeks resulted in 33%-100% of resolution of diarrhea in HIV individuals with cryptosporidiosis (Cello et al., 1991; Libertti et al., 1992; Moroni et al., 1993; Romeu et al., 1991). However, none of these studies showed a decreased number of Cryptosporidium oocysts excreted in stools. Similarly, another study using vapreotide for 14 days resulted in low clinical response and no parasite clearance (Girard et al., 1992). As the drug must be administered through an injection, local pain has been reported following the drug administration, along with nausea and abdominal pain (Cello et al., 1991; Girard et al., 1992). Drug-induced cholecystitis and pancreatitis associated with the use of octreotide has also been mentioned elsewhere (Romeu et al., 1991). According to the published reviewed data, the use of somatostatin analogues in intestinal cryptosporidiosis is limited to HIV-infected adults to relieve the possible debilitating symptoms of diarrhea in this population, yet does not provide notable results in parasite clearance.

3.5. Bovine colostrum and immunoglobulins

As it is rich in immunoglobulins, the hyperimmune bovine colostrum (HBC) derived from cow vaccination during gestation has been widely studied for its potential therapeutic actions in gastrointestinal infections (Steele et al., 2013). Earlier studies found that in Cryptosporidium-infected calves fed with HBC showed significantly fewer diarrheic episodes along with a shorter duration of oocyst shedding (Fayer et al., 1989; Perryman et al., 1999). The HBC has also been studied as the treatment or prevention of diarrhea caused by rotavirus, Shigella spp., enterotoxigenic E. coli, and Clostridium difficile (Steele et al., 2013). Current review addressed several studies on the use of HBC and bovine leukocyte extract (BLE) in the treatment of human cryptosporidiosis in small groups of individuals living with HIV (Table 5). Both HBC and BLE showed over 60% rate of clinical improvement with varying degrees of parasite clearance (Florén et al., 2006; Greenberg and Cello, 1996; McMeeking et al., 1990; Nord et al., 1990; Plettenberg et al., 1993; Rump et al., 1992). However, these studies included only small number of patients in either chronic cryptosporidiosis or severe diarrhea and a notable number of subjects lost to follow-up; therefore careful interpretation of the published results. Additionally, gastrointestinal upset associated with administration of HBC has been reported in some studies (Nord et al., 1990; Plettenberg et al., 1993).

3.6. Other therapeutic modalities

Although large number of studies on the treatment of human intestinal cryptosporidiosis has been performed using the drugs mentioned previously, there were published results of other treatment modalities as well (Table 5). These trials mainly were conducted as either open-label pilot studies after being demonstrated promising results on laboratory-based research on the active compound of the drugs or case reports (Amenta et al., 1999; Blanshard et al., 1997). Two studies on the use of letrozuril, a benzene acetonitrile commonly used as a chemophylactic drug for coccidian infections in domestic fowls, showed a poor cure rate of cryptosporidiosis (Harris et al., 1994; Loeb et al., 1995). These studies were performed in severely compromised HIV individuals, which might have been affected the overall results. Additionally, the presence of elevated alkaline phosphatases and other significant side effects halted further phase 2 trials of letrozuril (Harris et al., 1994; Loeb et al., 1995).

An open-label trial on 600 mg rifaximin administered 3 times daily for 14 days showed 100% of clinical and parasitological cure in HIV
Table 5
Studies on the use of other treatment modalities.

| Study                | Population                      | Size | Disease severity                | Drug(s)                          | Regimen                  | Comparison | Follow up period | Clinical improvement | Parasite clearance |
|----------------------|---------------------------------|------|---------------------------------|----------------------------------|--------------------------|------------|------------------|----------------------|---------------------|
| Nord et al. (1990)   | Individuals with HIV            | 5    | Chronic cryptosporidiosis       | Bovine colostrum (immune)        | 30 mg/ml For 10 days     | Bovine colostrum (non-immune) 20 ml/h | Daily            | 67% (2/3) vs. 0      | 67% (2/3) vs. 0     |
| Greenberg and Cello  (1996) | ≥18 yo with HIV (CD4 <200 cells/ul) | 20   | Severe presentation             | Bovine colostrum                 | 10 g powder QID for 21 days | For 10 days | Bovine colostrum 10 g capsule QID for 21 days | 92% (11/12) vs. 0 | 35% (7/20) in total |
| Flor et al. (2006)   | ≥18 yo with HIV (CD4 <200 cells/ul) | 20   | Severe presentation, dehydration | Bovine colostrum (ColoPlus)     | 50 g BID for 4 weeks     | None       | Week 1, 5, 7     | 100%                 | N/A                 |
| Rump et al. (1992)   | 1-54 yo with HIV and other immune deficiencies | 7    | All intensity                   | Bovine colostrum (Lactobin)     | 10 g OD for 10 days      | None       | Days 5, 10 20   | 71% (5/7)            | 71% (5/7)           |
| Plettenberg et al. (1993) | 26-58 yo with HIV (CD4 <100 cells/ul) | 7    | Chronic cryptosporidiosis       | Bovine colostrum (Lactobin)     | 10 g OD for 10 days      | None       | Days 5, 10 20   | 71% (5/7)            | N/A                 |
| McMeeking et al. (1990) | 31-46 yo with HIV                | 14   | Chronic cryptosporidiosis       | Bovine leukocyte extract (BLE)   | 5 IU Weekly for 8 weeks  | None       | Week 8           | 86% (6/7)            | 14% (1/7)³           |
| Liberti et al. (1992) | 37-70 yo with HIV (CD4 <100 cells/ul) | 4    | Severe diarrhea and dehydration | Octreotide                       | 50 mcg up to 500 mcg s.c. | None       | Day 21           | 100%                 | None                |
| Moroni et al. (1993)  | 21-60 yo with HIV (CD4 <100 cells/ul) | 13   | All intensity                   | Octreotide                       | 100 mcg s.c. TID for 2 weeks with increasing dose | None       | Week 4           | 61% (8/13)           | N/A                 |
| Cello et al. (1991)  | 18-60 yo with HIV                | 15   | Chronic cryptosporidosis with severe diarrhea | Octreotide (Sandostatin)        | 50 mcg up to 500 mcg s.c. TID for 2 weeks with increasing dose | None       | Days 14, 21 and 28 | 33% (5/15)           | N/A                 |
| Romeu et al. (1991)  | 22-48 yo with HIV                | 18   | All intensity                   | Octreotide (Sandostatin)        | 150 to 1500 mcg/day s.c. For 4 weeks | None       | Week 4           | 72% (13/18)          | N/A                 |
| Girard et al. (1992) | ≥18 yo with HIV                  | 21   | All intensity                   | Vapreotide                       | 400-500 mcg s.c. 2-6 times daily for 14 days | None       | Day 14           | 38% (8/21)           | None                |
| Harris et al. (1994) | 21-59 yo with HIV (CD4 <100 cells/ul) | 14   | All intensity                   | Letrazuril                       | 50 mg OD for 6 weeks     | None       | Week 10          | 50% (7/14)           | 50% (7/14)          |
| Loeb et al. (1995)   | 27-57 yo with HIV (CD4 <150 cells/ul) | 35   | All intensity                   | Letrazuril                       | 50 mg OD as long as the patient responded | None       | After day 7      | 66% (23/35)          | 40% (10/25)         |
| Amenta et al. (1999) | 12-54 yo with HIV                | 10   | All intensity                   | Rifaximin                        | 600 mg TID for 14 days   | None       | Day 14           | 100%                 | 100%                |
| Zulu et al. (2002)   | ≥18 yo with HIV (CD4 <200 cells/ul) | 4    | Chronic cryptosporidiosis       | Albendazole                      | 800 mg BID for 14 days   | None       | Weeks 3 and 6    | 60% (52/87)          | 100%                |
| Sinkala et al. (2011) | ≥18 yo with HIV and malnutrition | 7    | Chronic cryptosporidiosis       | Miltefosine                      | 2.5 mg/kg For 14 days    | None       | Week 4           | 29% (2/7)            | None                |
| Tam et al. (2020)    | 18-65 yo with advanced HIV       | 20   | Chronic cryptosporidiosis       | Cloroazimine                     | 50-100 mg TID            | Placebo    | Daily            | Worsening            | None                |
| Sindhu et al. (2014) | 6 months to 5 yo healthy children | 42   | All intensity                   | Probiotic Lactobacillus rhamnosus GG | Capsule (1x10-10 organisms) OD for 7 days | Placebo    | Week 4           | 35% (7/20)            | 36% (8/22)³         |

s.c.: subcutaneous.

³P < 0.05.

²Not statistically significant.

³ Either abatement of diarrhea or reduced stool frequency or volume.

⁴ Either complete eradication or reduction of oocyst number.
individuals with CD4 ≥200 cells/μL, with no notable side effects (Amenta et al., 1999). High dose of albendazole has also shown 100% parasite eradication after administration for 14 days in small number of patients with advanced HIV infection (Zulu et al., 2002). However, albendazole treatment yielded moderate gastrointestinal side effects in the study (Table 6). Despite promising results of parasitic multiplication inhibition in in vitro studies, miltefosine and clofazimine did not show exceptional results on clinical improvement, and none of the patients in the trials showed Cryptosporidium clearance (Sinkala et al., 2011; Tam et al., 2020). Furthermore, significant side effects were reported following the administration of miltefosine: elevated liver transaminases and renal failure (Sinkala et al., 2011). Worsening diarrhea episodes were also noted in patients taking clofazimine (Tam et al., 2020). The use of probiotics in the treatment of intestinal cryptosporidiosis showed no differences in reducing diarrhea severity compared to placebo (Sindhu et al., 2014). Many of these trials were terminated due to futility.

4. Recommendations and future directions

Current review addressed diverse therapeutic modalities that have been used in clinical trials with different results that may be implemented in various settings. Nitazoxanide is the most frequently studied drug for the treatment of human intestinal cryptosporidiosis. Based on current review, a possible recommendation on the use of nitazoxanide will be the age-adjusted dose of 100 mg–500 mg given twice daily for 3 days, preferably in immunocompetent patients of all ages (Abaza et al., 2016; Amadi et al., 2002; Hussien et al., 2013; Rossignol et al., 2001, 2006), whereas in HIV individuals nitazoxanide did not demonstrate superiority than placebo (Amadi et al., 2009; Rossignol et al., 1998). The use of 500 mg of paromomycin, 3 to 4 times daily for a minimum of 14 days showed an exceptional cure rate of cryptosporidiosis, particularly in HIV-infected adults with CD4 ≥200 cells/μL (Bissuel et al., 1994; Fichtenbaum et al., 1993), and not in severely compromised HIV patients (Flaminian et al., 1996; Hewitt et al., 2000; Smith et al., 1998; White et al., 1994). The efficacy of paromomycin, however, was found to be inferior to nitazoxanide (Hussien et al., 2013). According to the results of the controlled trials included in the current review, the use of macrolide antibiotics showed no effective results in both clinical and parasitological improvement. The use of HBC and BLE was limited to only reducing the severity of diarrhea in immunocompromised patients (Floren et al., 2006; Greenberg and Cello, 1996; McMeeking et al., 1990; Nord et al., 1990; Plettenberg et al., 1993; Rump et al., 1992), and should possibly be administered as a complementary therapeutic drug along with other antimicrobials to reach optimal parasite eradication. Nevertheless, other than the efficacy itself, side effects should also be considered especially when the drugs are to be administered in higher doses or in a longer therapeutic regimen. The availability of drugs must be noted, as some drugs may not be available in less-developed countries. Our review demonstrated a wide variety of therapeutic options for human intestinal cryptosporidiosis. However, the number of patients included in majority of the studies was very small, and the disease spectrum and progression in which the studies were conducted was generally limited. The degree of immune suppression in HIV individuals may also play a role in clinical manifestations and therapeutic responses, as HIV-seropositive individuals with preserved CD4 levels might have had comparable immune response with that of immunocompetent individuals. Additionally, careful interpretation of data should be taken especially on the severity of diarrhea and the number of oocysts prior to any therapeutic modalities to justify the effectiveness of the treatment. This should encourage further large prospective studies in wide range of patients, both immune-competent and -compromised, and asymptomatic individuals.

Studies on the treatment of human cryptosporidiosis are generally hindered, particularly due to lack of comprehensive understanding on its immune response and mechanisms of parasite clearance, and that animal models often yielded different results in clinical trials (Sparks et al., 2015). However, more studies on novel drug targets have been performed, these include the Cryptosporidium calcium-dependent protein kinases (Castellanos-Gonzalez et al., 2013; Choi et al., 2020; Murphy et al., 2010), serine and cysteine proteases (Forney et al., 1996; Ndao et al., 2013), lipid kinase (Manjunatha et al., 2017), dihydrofolate reductase (Kumar et al., 2014), nucleoside diphosphate kinase (Castellanos-Gonzalez et al., 2020; Castellanos-Gonzalez et al., 2019), inosine monophosphate dehydrogenase (Ghara et al., 2014; Jefferies et al., 2015), and fatty acid metabolisms (Bessoff et al., 2010; Chattopadhyay and Mahapatra, 2019). Although most of these novel drug candidates have progressed through animal studies, some of these compounds were ineffective or were potentially toxic with remarkable side effects hence should be carefully selected for further development (Wang et al., 2020). In addition to introducing effective drugs to overcome the currently limited available therapeutic options for human cryptosporidiosis, raising public health awareness on the high risk of parasite transmission in a specific population of individuals should also be set in motion for better disease management and control (Ashigbie et al., 2021).

5. Conclusions

Current review highlights the evidences and gaps of antiparasitic treatments for human intestinal cryptosporidiosis in the past decades. Diverse therapeutic modalities in clinical trials showed various results, among which several treatments have suggested efficacy in different population and settings. However, there is inadequate data regarding

Table 6
Reported side effects of various drugs used for treatment of human intestinal cryptosporidiosis.

| Drugs                      | Side effects* | References                                      |
|----------------------------|---------------|------------------------------------------------|
| Nitazoxanide               | Nausea, vomiting, abdominal pain, fatigue, drowsiness, headache, dizziness, skin rash, scleral and urine discoloration, anorexia, worsening diarrhea, dry mouth, constipation | (Ali and Kumar, 2015; Amadi et al., 2009; Rossignol et al., 1998, 2001, 2006) |
| Paromomycin                | Nausea, abdominal pain, elevated alkaline phosphatases | (Bissuel et al., 1994; Fichtenbaum et al., 1993; Hewitt et al., 2000; Smith et al., 1998) |
| Macrolides (azithromycin, spiramycin, roxithromycin, erythromycin) | Nausea, abdominal pain, vomiting, skin rash, elevated liver transaminases, worsening diarrhea | (Connolly et al., 1988; Dionisio et al., 1998; Sprinz et al., 1998; Uip et al., 1998) |
| Somatostatin analogue (octreotide, vaprootide) | Local pain at injection site, abdominal pain, nausea, fever, cholecystitis and pancreatitis | (Cello et al., 1991; Girard et al., 1992; Romeu et al., 1991) |
| Bovine colostrum and immunoglobulin | Nausea, vomiting, abdominal pain | (Nord et al., 1990; Pettenberg et al., 1993) |
| Letrazuril                 | Skin rash, elevated alkaline phosphatases, worsening diarrhea, fever | (Harris et al., 1994; Loeb et al., 1995) |
| Rifaximin                 | None | Amenta et al. (1999) |
| Albendazole               | Nausea, vomiting | Zulu et al. (2002) |
| Miltefosine               | Elevated liver transaminases, renal failure, intestinal obstruction, visual acuity impairment | (Sinkala et al., 2011) |
| Clofazimine               | Worsening diarrhea, abdominal pain, nausea, vomiting, malaise, anorexia | Tam et al. (2020) |
| Probiotics                | None | Sindhu et al. (2014) |

* Written from the most to the least commonly reported side effects.
controlled trials to suggest the use of these treatment modalities. Currently available data is intended to aid the development of strategies for improving access to treatments in different clinical settings, as well as to help guide further studies on anti-Cryptosporidium drugs.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and material
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Funding
This review did not receive any specific funding.

Author’s contributions
AD performed article extraction. Both AD and IPS conducted manuscript writing. All authors have read and approved the final manuscript.

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

List of Abbreviations

AIDS acquired immunodeficiency syndrome
ARV antiretroviral
BID twice daily
BLE bovine leukocyte extract
CD4 T-helper cells
FDA Food and Drug Administration
GHII growth hormone-inhibiting hormone
HBC hyperimmune bovine colostrum
HIV human immunodeficiency virus
IFA immunofluorescence antibody
OD once daily
PCR polymerase chain reaction
PFOR pyruvate:ferredoxin oxidoreductase
QID four times daily
RCT randomized controlled trial
TID three times daily

References
Ahaza, B.E., Hamza, R.S., Farag, T.I., Abdel-Hamid, M.A., Mostafa, R.A., 2016. Assessing the efficacy of nitazoxanide in treatment of cryptosporidiosis using PCR examination. J. Egypt. Soc. Parasitol. 46, 683–692.
Adeyemo, F.E., Singh, G., Reddy, P., Bux, F., Steenstra, T.A., 2019. Efficiency of chlorine and UV in the inactivation of Cryptosporidium and Giardia in wastewater. PloS One 14 e0216040.
Ahmadpour, E., Safarpour, H., Xiao, L., Zarean, M., Hatam-Nahavandi, K., Barac, A., Picot, S., Rahimi, M.T., Rubino, S., Mahami-Oskouei, M., Spotin, A., Nami, S., Baghi, H.B., 2020. Cryptosporidiosis in HIV-positive patients and related risk factors: a systematic review and meta-analysis. Parasite 27, 27-27.
Ali, S., Kumar, S., 2015. Treatment outcomes with nitazoxanide in immunocompetent adults naive patients with cryptosporidiosis; do we need combination therapy with paromomycin or azithromycin? Trop Med Surg 3.
A. Ditypanusa and I.P. Sari

International Journal for Parasitology: Drugs and Drug Resistance 17 (2021) 128–138

137

Flanigan, T.P., Ramratnam, B., Graether, C., Hellinger, J., Smith, D., Wheeler, D., Hawley, E., Heath-Chiozzi, M., Ward, D.J., Brummitt, C., Turner, J., 1996. Prospective trial of paromomycin for cryptosporidiosis in AIDS. Am. J. Med. 100, 370–372.

Flore, C.H., Chinenye, S., Elfrstrand, L., Hagman, C., Ilse, L., 2006. ColiPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhea. Scand. J. Gastroenterol. 41, 1252–1257.

Forney, J.R., Yang, S., Da, C., Healey, M.C., 1996. Efficacy of serine protease inhibitors against Cryptosporidium parvum infection in a bovine fallopian tube epithelial cell co-culture system. J. Parasitol. 82, 638–640.

Gerace, E., Lo Presti, V.D.M., Bianco, C., 2019. Cryptosporidium infection: epidemiology, pathogenesis, and differential diagnosis. Eur J Microbiol Immunol (Bp) 9, 119–123.

Ginns, A., Cipolla, O., Scaline, G., 1996. In-vitro activity of macrolides alone and in combination with artemisinin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. Antimicrob. Chemother. 38, 399–408.

Girard, P.M., Goldschmidt, E., Vittecoq, D., Massip, P., Gastiaburu, J., Meyohas, M.C., Girard, P.M., Goldschmidt, E., Vittecoq, D., Massip, P., Gastiaburu, J., Meyohas, M.C., Gorla, S.K., McNair, N.N., Yang, G., Gao, S., Hu, M., Jala, V.R., Haribabu, B., Striepen, B., Cuny, G.D., Mead, J.R., Hedstrom, L., 2014. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob. Agents Chemother. 58, 1603–1614.

Greenberg, P.D., Cello, J.P., 1996. Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology. 13, 348–354.

Harris, M., Deutsch, G., MacLean, J.D., Tsoukas, C.M., 1994. A phase I study of letrozulin in AIDS-related cryptosporidiosis. AIDS 8, 1109–1113.

Hewitt, R.G., Pinnock, C.T., Higgs, E.S., Carey, J.T., Gie, S.A., Royle, R., Beven, R., Fooks, A.R., Wright, J.S., Villanueva, R., 2015. Target validation of thymidylate synthase–dihydrofolate reductase. Bioorg. Med. Chem. Lett. 24, 3536–3540.

White Jr., A.C., Jorgensen, W.L., Anderson, K.S., 2014. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase. Biochem. Biophys. Res. Commun. 450, 640–645.

Hossain, M.J., Akinsola, A., Mandomando, I., Nhampossa, T., Acker, H., Bron, S., Black, K.A., Peterson, D.E., Kaznec-zaric, J.J., Addis, D.G., Fox, K.R., Rose, J.B., et al., 1994. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med. 331, 164–172.

Manzanar, R., Vinayak, S., Zambris, A.J., Chao, A.T., Sy, T., Noble, C.G., Bonamy, G.M.C., Kondreddi, R.R., Zou, B., Gedeck, P., Brooks, C.F., Herbert, G.T., Sateriale, A., Tandel, J., Nob, S., Lakshminarayana, S.B., Lim, S.H., Goodman, L.B., Cooper, J.R., Fong, G., Chang, L., Blas, F., Wagner, J., Leong, P.J., Striepen, B., Dias, T.A., 2017. A Cryptosporidium P41RK inhibitor is a drug candidate for cryptosporidiosis. Nature 546, 376–380.

Marshall, R.J., Flanigan, T.P., 1996. Paromomycin inhibits cryptosporidiosis infection of the in vivo human enterocyte assay. Microbes Infect. 165, 772–774.

Marr, T.E., Campagnoli, L., Siboni, E., Goff, M., Pizzo, P.A., 1990. Long-term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report. J. Chemotherapy. 10, 474–475.

McCann, M.D., 2019. Cryptosporidium enteritis in an immunosuppressed child: applying the adult HIV treatment regimen. Pediatrics 144, 592.

McMeekin, A., Borkowski, W., Klesius, P.H., Bonk, S., Holzmann, R., Lawson, H.S., 1990. A controlled trial of bovine dairyalted lacteoyl extract for cryptosporidiosis in patients with AIDS. J. Infect. Dis. 161, 108–112.

Meisel, J.L., Pereira, D.R., Meligrino, C., Ruben, C.E., 1976. Overwheeling watery diarrhea associated with a cryptosporidium in an immunosuppressed patient. J. Infect. Dis. 133, 235–237.

Naluri, P., Kande, R., Peddie, A., Noh, S., Lakshminarayana, S.B., Lim, S.H., Goodman, L.B., Cooper, J.R., Fong, G., Chang, L., Blas, F., Wagner, J., Leong, P.J., Striepen, B., Dias, T.A., 2017. A Cryptosporidium P41RK inhibitor is a drug candidate for cryptosporidiosis. Nature 546, 376–380.

Nimura, F.A., Burek, J.D., Page, D.L., Holzmann, C., Yardley, J.H., 1976. Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. Am. J. Pathol. 84, 337–344.

Norris, R.M., oxley, D., Potter, N.J., Drummond, A., Aranseu, A., El-Shenn, A.S., El-Bader, M.M., 2013. Comparative study between the effect of nitazoxanide and paromomycin in treatment of cryptosporidiosis in hospitalized children. J. Egypt. Soc. Parasitol. 43, 463–470.

Ogul, K., Akin, S., Kaylan, M., 2015. Parasitic diseases in irritable bowel syndrome: a case-control study. World J. Gastrointest. Pharmacol. Therap. 8, 201–207.

Rueger, R., Yang, R., Rohr, M.C., Weller, L., Mende, M., Schuster, J., Herrmann, D., 2010. Long-term treatment with clarithromycin in patients with HIV-associated cryptosporidiosis. AIDS 24, 1491–1498.

Riemann, J., Koepke, C., Sorensen, A., Nielsen, D., 2006. Investigation of calcium-dependent protein kinase 1 (CDPK1) from C. Parvum and T. Gondii. ACS Chem. Biol. 1, 333–337.

Ndaa, M., Nath-Chowdhury, M., Sakai, M., Viscaino, S., Robins, M., Nishiyama, S., McCann, P., Engel, J., Bickle, E., Ethier, J., 1992. Treatment of AIDS-related refractory diarrhea with octreotide. Digestion 54 (Suppl. 1), 30–32.

Kamal, M., Al-Saadi, S., Al-Mufti, M., Al-Yamani, A., Al-Rahoumi, M., Al-Jameel, A., 2013. Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. J. Infect. Dis. 207, 202–209.

Kamal, M., Al-Saadi, S., Al-Mufti, M., Al-Yamani, A., Al-Rahoumi, M., Al-Jameel, A., 2013. Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. J. Infect. Dis. 207, 202–209.

Kamal, M., Al-Saadi, S., Al-Mufti, M., Al-Yamani, A., Al-Rahoumi, M., Al-Jameel, A., 2013. Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. J. Infect. Dis. 207, 202–209.

Kamal, M., Al-Saadi, S., Al-Mufti, M., Al-Yamani, A., Al-Rahoumi, M., Al-Jameel, A., 2013. Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. J. Infect. Dis. 207, 202–209.
Sáez-Llorens, X., Odio, C.M., Umana, M.A., Morales, M.V., 1989. Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium. Pediatr. Infect. Dis. 7, 136–140.

Samie, A., Al-Qahtani, A., El Bakri, A., Ehsaie, B., 2015. Challenges and innovative strategies to interrupt cryptosporidium transmission in resource-limited settings. Curr Trop Med Rep 2, 161–170.

Shirley, D.A.T., Moosah, S.N., Klotz, K.L., 2012. Burden of disease from cryptosporidiosis. Curr. Opin. Infect. Dis. 25, 555–563.

Sinkala, E., Katubulushi, M., Sianongo, S., Obwaller, A., Kelly, P., 2011. In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. Ann. Trop. Med. Parasitol. 105, 129–134.

Smith, N.H., Cron, S., Valdez, L.M., Chappell, C.L., White Jr., A.C., 1998. Combination drug therapy for cryptosporidiosis in AIDS. J. Infect. Dis. 178, 900–903.

Sparks, H., Nair, G., Castellanos-Gonzalez, A., White Jr., A.C., 2015. Treatment of cryptosporidiosis: what we know, gaps, and the way forward. Curr Trop Med Rep 2, 181–187.

Uip, D.E., Lima, A.L., Amato, V.S., Boulos, M., Neto, V.A., Bem David, D., 1998. Roxythromycin treatment for diarrhea caused by Cryptosporidium spp. in patients with AIDS. J. Antimicrob. Chemother. 41 (Suppl. B), 93–97.

Ursini, T., Moro, L., Requeses-Mendez, A., Bertoli, G., Buonfrate, D., 2020. A review of outbreaks of cryptosporidiosis due to unpasteurized milk. Infection 48, 659–663.

Wang, B., Castellanos-Gonzalez, A., White Jr., A.C., 2020. Novel drug targets for treatment of cryptosporidiosis. Expert Opin. Ther. Targets 24, 915–922.

White Jr., A.C., Chappell, C.L., Hayat, C.S., Kimball, K.T., Flanigan, T.P., Goodgame, R.W., 1994. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J. Infect. Dis. 170, 419–424.

Wittenberg, D.F., Miller, N.M., van den Ende, J., 1989. Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J. Infect. Dis. 159, 131–132.

Zulu, I., Veitch, A., Sianongo, S., McPhail, G., Feakins, R., Farthing, M.J., Kelly, P., 2002. Albendazole chemotherapy for AIDS-related diarrhoea in Zambia—clinical, parasitological and mucosal responses. Aliment. Pharmacol. Ther. 16, 595–601.